Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 8/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.41 |
| ▸ | JUN | P05412 | 2/20 | 0.41 |
| ▸ | IGF1R | P08069 | 7/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3234316 | 0.80 | CDK2 (0.46) | KITCDK2MAPK8IRAK4MAPK9 | |
| SCHEMBL376702 | 0.78 | KIT (0.44) | KITCDK2MAPK8IRAK4MAPK9 | |
| SCHEMBL377088 | 0.74 | IRAK4 (0.40) | CDK2MAPK8IRAK4MAPK9MAPK10 | |
| SCHEMBL376539 | 0.74 | IRAK4 (0.40) | CDK2MAPK8IRAK4MAPK9MAPK10 | |
| SCHEMBL12553163 | 0.72 | IRAK4 (0.53) | KITCDK2MAPK8IRAK4MAPK9 | |
| SCHEMBL23459270 | 0.70 | ATM (0.45) | — | |
| SCHEMBL23459370 | 0.70 | ATM (0.45) | — | |
| SCHEMBL1994913 | 0.64 | ADORA2A (0.41) | IRAK4 | |
| SCHEMBL1997321 | 0.64 | KIT (0.64) | KITCDK2MAPK8IRAK4MAPK9 | |
| SCHEMBL1997512 | 0.63 | DYRK1A (0.52) | KITCDK2IRAK4MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2328890-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | Pfizer Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | KIT 324/4885CDK2 157/4885MAPK8 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.